Elicio Therapeutics Report the First Patient Dosing of ELI-002 7P in P-I/II Trial for KRAS/NRAS Mutated Solid Tumors
Shots:
- The P-I/II clinical trial (AMPLIFY-7P) evaluates the safety & efficacy of ELI-002 7P in patients with KRAS/NRAS mutated solid tumors. The P-Ia and P-Ib portions of the study will show the RP2D & evaluate 3 dose expansion cohorts, respectively, while P-II will enroll additional patients to be assessed in a 2:1 randomized cohort of ELI-002 7P vs observation
- The P-I/II clinical trial (AMPLIFY-7P) is designed based on the data obtained from the ongoing P-I clinical trial (AMPLIFY-201) evaluating a 2-peptide formulation of ELI-002
- ELI-002 is an investigational cancer vaccine developed using Elicio’s proprietary lymph node targeting Amphiphile (AMP) technology. ELI-002 7P contains 7 KRAS & NRAS peptide-based antigens (G12D, G12R, G12V, G12A, G12C, G12S, G13D)
Ref: Elicio Therapeutics | Image: Elicio Therapeutics
Related News:- Elicio Therapeutics Entered into a Definitive Merger Agreement with Angion to Advance ELI-002 for Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
